FDA Peptide Reclassification 2026: Complete Guide to What Changed

Overview: Why 2025–2026 Marks a Turning Point

The past two years have produced the most significant regulatory restructuring of the peptide sector since the FDA's initial bulk drug substance guidance framework was introduced. A combination of expanded Category 2 designations, landmark GLP-1 approval milestones, and new compounding restrictions has fundamentally changed how researchers, clinicians, and compounding pharmacies interact with peptide compounds.

This guide consolidates every major development into a single reference, covering regulatory timelines, practical implications, and what the landscape looks like heading into the remainder of 2026.

BPC-157 and the Category 2 Designation

What Category 2 Actually Means

The FDA's 503A/503B bulk drug substance nomination process divides compounds into three outcomes: Category 1 (may be used in compounding, nominated and under review), Category 2 (nominated but placed on the "do not compound" list), and Category 3 (insufficient data to evaluate). A Category 2 designation does not constitute a finding that a substance is unsafe — it means the FDA has determined that there is insufficient clinical evidence to support its use in compounding under current standards, or that it presents a potential safety concern that outweighs the clinical need.

BPC-157 (Body Protection Compound-157) was formally moved to Category 2 status in late 2024, following a period of extended FDA review initiated in 2023. The practical consequence: 503A compounding pharmacies serving individual patients and 503B outsourcing facilities operating under the DQSA may no longer compound preparations containing BPC-157 for human use.

What Preceded the Decision

The FDA's review of BPC-157 focused on several areas of concern. First, the compound lacks approved drug status in any major regulatory jurisdiction, meaning there is no FDA-accepted clinical trial package or NDA/BLA demonstrating safety and efficacy for human therapeutic use. Second, the available animal data — while suggestive of interesting biological activity across gastrointestinal, musculoskeletal, and neurological systems — was deemed insufficient to bridge to human dosing or safety profiles. Third, the agency flagged the widespread off-label compounding of BPC-157 as occurring largely outside the physician-patient relationship framework compounding rules are designed to protect.

Enforcement Timeline and Transition Period

The FDA issued warning letters to several compounding pharmacies in Q1 and Q2 of 2025 that continued to compound BPC-157 after the Category 2 designation took effect. The agency has stated that it considers continued compounding of Category 2 substances to be a violation of the FDCA's compounding provisions and subject to enforcement action, including injunctions and seizure.

A small number of 503B facilities petitioned for a transition period citing pre-existing patient relationships. The FDA declined to grant a formal transition period but indicated it would exercise enforcement discretion on a case-by-case basis through mid-2025 for documented clinical situations.

Semaglutide and Tirzepatide: The Shortage Saga Closes

Compounding Under Shortage Status

Perhaps the most economically significant peptide regulatory story of 2024–2025 was not a restriction, but a permission: the GLP-1 receptor agonists semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) were both designated by the FDA as being in shortage, which permitted 503A and 503B compounders to produce copies of these drugs under shortage-based compounding provisions.

The shortage designations created a multi-billion dollar compounding market nearly overnight. Hundreds of compounding pharmacies — many with no prior GLP-1 experience — began producing semaglutide and tirzepatide injections for patients who could not access branded products.

The Shortage Ends — and So Does Most Compounding

Beginning in late 2024, the FDA began the process of removing both semaglutide and tirzepatide from the shortage list. The removal of tirzepatide from the shortage list was finalized in Q4 2024, with the FDA issuing guidance that 503B outsourcing facilities had until a specified date to cease production and distribution. 503A compounding pharmacies faced a similar but slightly extended wind-down timeline.

Semaglutide's shortage designation removal followed in early 2025, triggering similar compliance deadlines. Both decisions were contested by the Alliance for Pharmacy Compounding and several individual outsourcing facilities, resulting in ongoing litigation as of late 2025. Federal courts have so far declined to issue injunctions blocking the FDA's removal of the shortage designations.

What Compounders Can Still Do

Certain compounding of GLP-1 compounds remains permissible under narrow circumstances. 503A pharmacies may still compound semaglutide or tirzepatide for individual patients who have a documented allergy or intolerance to a specific inactive ingredient in the commercially available product — provided the prescribing physician documents this need. Compounding that merely produces a lower-cost copy of an available branded product is not permissible under this exception.

503B outsourcing facilities face stricter standards and generally cannot compound copies of commercially available drug products outside of shortage status.

Implications for Research Institutions and Investigators

The Research Use Distinction

A critical point that is frequently misunderstood: the FDA's compounding rules apply to drugs compounded for human therapeutic use, not to research-grade compounds obtained by research institutions under separate frameworks. Academic and commercial research entities obtaining peptides for in vitro studies, animal research, or federally regulated human clinical trials operate under different legal authorities (the FDCA's research exemptions, IND framework, etc.).

The reclassification of BPC-157 to Category 2 does not prohibit a university laboratory from purchasing research-grade BPC-157 from a qualified supplier for preclinical work. It prohibits a compounding pharmacy from preparing it for human patients.

Implications for Clinicians

For physicians who were utilizing compounded BPC-157 in patient care — whether through formal compounding pharmacy relationships or grey-market sources — the path forward is limited. There is no FDA-approved BPC-157 product, no active IND permitting its human use outside of formal trials, and no compounding exemption available. Clinicians should consult with legal counsel regarding any continued use of such compounds in patient care.

The Pipeline Consideration

Several biotechnology companies have initiated IND-enabling studies for BPC-157 analogs, and at least one company has reported submitting a Phase I IND application to the FDA. If clinical trials proceed and generate positive safety and efficacy data, a future NDA could theoretically create a pathway to approval — and potentially to subsequent compounding eligibility under different rules. That outcome, however, remains speculative and is years away at minimum.

Looking Ahead: What to Watch in 2026

Several developments merit attention in the coming months:

Category 2 enforcement intensity. The FDA has signaled that it intends to increase enforcement activity against compounders selling Category 2 substances. Surveillance of online pharmacy platforms and wholesale peptide distributors is expected to intensify.

GLP-1 litigation outcomes. The outcome of ongoing federal litigation challenging the FDA's shortage removal decisions for semaglutide and tirzepatide could have broad precedent-setting implications for how shortage designations are managed in the future.

New nominations. Several peptides currently in Category 1 review — including Selank, Semax, and PT-141 — may receive final disposition in 2026. Researchers and clinicians relying on compounded versions of these compounds should monitor FDA Federal Register notices.

State-level variation. Some states have enacted or are considering legislation that creates state-level compounding frameworks with different standards than federal law. The interaction between state compounding law and FDA enforcement remains an area of active legal development.

Summary Table

This table reflects the regulatory status as of January 2026. Designations are subject to change. Always consult the FDA's current bulk drug substances list for authoritative status.